Find your next paid study

M.D. Anderson Cancer CenterNCT04751409

~$10 – $6,250

Digital Biomarker and Omics-Based Assessment of Surgical Resiliency in Children Undergoing Solid Tumor Resection: A Pilot Feasibility Study

This observational study is to better understand how children and their families recover after the stress of major surgery for cancer so that investigators can…

Pediatric CancerNeuroblastomaSarcoma+10 more

Glaucoma, Open-anglePrimary Open Angle Glaucoma (POAG)

~$10 – $750

Mayo ClinicNCT06674811

Phase 2

NADIR Trial: A Principal Investigator-Initiated, Single-Center, Open-Label, Active-Controlled Phase 2a Study of High-Dose Nicotinamide (Vitamin B3) Supplementation in Adults With Mild to Moderate Primary Open-Angle Glaucoma (POAG)

The goal of this clinical trial is to learn whether a high-dose vitamin B3 supplement called nicotinamide can protect retinal nerve cells in adults with primar…

University of ChicagoNCT07808333

~$10 – $6,250

A Phase 1, Multicenter, Open-Label, Ascending-Dose and Phase 2, Randomized, Double-Masked, Sham-Controlled, Clinical Study to Evaluate the Safety and Efficacy of ASP2767 in Participants With Optic Neuropathy Due to Glaucoma

Open-angle glaucoma is the most common type of glaucoma, a disease that damages the nerves in the eye and can lead to vision loss. Current treatments include e…

Glaucoma

Astellas Pharma Global Development, Inc.NCT07770685

Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas

To learn about the financial stress patients undergoing surgery to treat orthopedic cancer experience because of the costs of cancer care, and to learn about t…

Bone SarcomasFinancial Toxicity

M.D. Anderson Cancer CenterNCT07215611

~$10 – $750

Metastatic Soft Tissue SarcomaUnresectable Soft Tissue Sarcoma

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.

Retroperitoneal SarcomaLiposarcomaLeiomyosarcoma

~$10 – $7,500

Adcendo ApSNCT06797999

Phase 3

A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves t…

European Organisation for Research and Treatment of Cancer - EORTCNCT04031677

~$10 – $7,500

Endometrial NeoplasmsSoft Tissue Sarcoma (STS)Breast Neoplasms

Phase 1b/2a Clinical Study of AL58805 Combining With Other Anti-tumor Agents in Advanced, Metastatic GYN, STS or Breast Cancers

This phase 1b/2a study evaluates AL58805, an oral investigational drug that blocks PI3K and mTOR signaling, in combination with one of three anticancer treatme…

Advenchen Pharmaceuticals, LLC.NCT07811232

Phase 2

Phase II Trial O6-benzylguanine(BG) and Temozolomide(TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140K MGMT+Hematopoietic Progenitors to Protect Hematopoiesis

This phase II trial studies the effect of P140K MGMT hematopoietic stem cells, O6-benzylguanine, temozolomide, and carmustine in treating participants with sup…

Glioblastoma MultiformeGlioblastoma Multiforme, AdultSupratentorial Glioblastoma+1 more

Leland MethenyNCT05052957

~$10 – $7,500

Endometrial NeoplasmsOvarian NeoplasmsSoft Tissue Sarcoma (STS)+1 more

Phase 1b/2a Clinical Study of Catequentinib Hydrochloride (AL3818) Monotherapy or Combining Therapy With Other Anti-tumor Agents in Advanced, Metastatic Endometrial, Low Grade Serous Ovarian Cancer (LGSOC), STS or GBM Cancers

This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (C…

Advenchen Pharmaceuticals, LLC.NCT07811297

CancerAdvanced CancerLocally Advanced Carcinoma+8 more

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various …

Angiex, Inc.NCT06440005

Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor

The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alo…

GlioblastomaGliosarcoma